Norbert Bischofberger, executive vice president of research and development and chief scientific officer of Gilead Sciences (NASDAQ: [[ticker:GILD]]), is stepping down after nearly 30 years with the company. Foster City, CA-based Gilead says Bischofberger will leave his position at the end of April but remain with the company through July. John McHutchison, who is currently executive vice president of clinical research, has been named Bischofberger’s successor.
In other moves, Gilead announced that Andrew Cheng, executive vice president of clinical research and development operations, will be appointed chief medical officer. Gilead says Cheng will continue leading the company’s HIV clinical research program while taking on responsibility for its medical affairs.
